Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Trial Profile

A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Tigercat Pharma
  • Most Recent Events

    • 20 Feb 2018 Results presented in a Menlo Therapeutics media release.
    • 20 Feb 2018 Data assessing the safety and efficacy in this trial was published in the Journal of the American Academy of Dermatology, according to a Menlo therapeutics media release.
    • 17 Feb 2018 Results published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top